Injective token surged for a second day, trading around $9.25 and adding nearly 30% over the prior 24 hours, as momentum improved and exchange balances declined. The rebound comes after a recovery from levels around the 50-day Exponential Moving Average near $6.59 last week, with the token moving back above the closely watched $8.21 area.
Key takeaways
- Price move: Injective’s token rose to about $9.25, up nearly 30% in 24 hours.
- Catalyst: Renewed focus on Injective’s tokenization and onchain finance push, following CEO Eric Chen’s meetings with US officials.
- Market signal: Data cited by Santiment showed fewer tokens on exchanges and improved positioning for holders as prices moved higher.
- Implication: Technical levels regained—especially above $8.21—raise the odds of a test of the October 13 high near $10.09, though follow-through demand is needed.
What drove the move
The rally followed a strong shift in trading conditions and positioning signals. According to Santiment data referenced in the report, Injective’s social dominance rose to 1.1% on Friday, indicating a larger share of tracked cryptocurrency discussion centered on the token.
At the same time, Santiment’s onchain figures pointed to a reduction in immediate sell pressure. Exchange supply fell to 872,500 INJ from about 1.26 million INJ on August 12. Over the same period, holdings at leading non-exchange wallets increased from 94.99 million to 95.46 million tokens.
While withdrawals from exchanges can reflect longer-term holding, the report noted the figures do not confirm investor intent or rule out future selling. Still, the combination of higher attention and declining exchange inventory contributed to a more constructive near-term backdrop for buyers.
Separately, the price advance coincided with increased scrutiny of Injective’s tokenization strategy after CEO Eric Chen met with senior US officials. Injective said Chen met with White House officials as well as the Securities and Exchange Commission and the Commodity Futures Trading Commission, with discussions focused on advancing tokenization and onchain finance within US regulatory frameworks.
Market reaction and positioning
From a broader investor perspective, the reported change in circulating profitability also mattered. The report said the percentage of circulating supply in profit climbed to 77.01%, compared with 41.16% at an earlier reference point. That reflects improved positions for existing holders as prices recovered.
However, higher profitability can cut both ways: it may support confidence, but it also means more holders have potential gains available to realize if momentum fades. In other words, the same factors that helped drive renewed interest could also set up a supply response if prices stall near key resistance levels.
Technical picture: $8.21 reclaim targets $10.09
On the chart, the rebound strengthened a bullish technical setup. The report described Injective trading above its 50-day Exponential Moving Average near $6.94 and its 200-day EMA around $5.76. It also said the Moving Average Convergence Divergence indicator remains positive, with a modestly positive histogram.
Momentum indicators were also supportive but not extreme. The Relative Strength Index was reported near 66—above the midpoint but below the conventional overbought level of 70—suggesting upward momentum without a clear sign of exhaustion.
Crucially, the token’s move back above $8.21 improves the recovery structure. The report said holding that breakout would put the October 13 high near $10.09 into focus. If buyers can clear $10.09, the October 10 high at $12.44 was identified as the next upside reference.
Conversely, the $8.21 level is described as an initial test for whether demand can hold during any pullback. Below it, the report pointed to the 50-day EMA near $6.94 as a stronger technical support area, with the 200-day EMA around $5.76 offering a deeper reference for the broader trend.
Bigger picture for investors
Beyond short-term price action, the news flow around Injective’s regulatory engagement may continue to influence trader attention. Injective said the meetings covered tokenization and onchain finance topics, and the project highlighted regulatory-related developments including SEC-registered transfer agent status for tokenized securities, CFTC-regulated INJ futures, and an Injective mint initiative for real-world assets. The team also said Injective would be “coming to Wall Street soon,” according to earlier announcements referenced in the report.
Still, investors are likely to treat the meetings as supportive context rather than proof of causality for the rally. As the report itself cautioned, the attention linked to policy discussions does not establish that the meetings directly caused the price recovery.
With the token now back above a key technical threshold, the next signal investors will watch is whether INJ can sustain demand around $8.21 and build momentum toward $10.09. A failure to hold the breakout would increase the odds of a revisit to intermediate supports, while continued strength could shift focus to the next resistance band near the October highs.
What to watch next: traders will likely monitor INJ’s ability to hold above $8.21, follow-through toward $10.09, and whether exchange balances continue to decline alongside improving onchain positioning. Additional updates on Injective’s regulatory and tokenization efforts—and broader risk sentiment across digital-asset markets—could also affect near-term volatility.
